Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST6GAL1 | P15907 | 11/20 | 0.50 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sialic Acid SCHEMBL30081458 | 1.00 | ST6GAL1 (0.50) | ST6GAL1NANPTSHRGLAP2RY2 | |
| Sialic Acid SCHEMBL30081457 | 1.00 | ST6GAL1 (0.50) | ST6GAL1NANPTSHRGLAP2RY2 | |
| Sialic Acid SCHEMBL29668373 | 1.00 | ST6GAL1 (0.50) | ST6GAL1NANPTSHRGLAP2RY2 | |
| Sialic Acid SCHEMBL21068057 | 1.00 | ST6GAL1 (0.50) | ST6GAL1NANPTSHRGLAP2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL5094677 | 0.95 | ST6GAL1 (0.50) | ST6GAL1TSHRGLAP2RY2 | |
| Sialic Acid SCHEMBL28452247 | 0.94 | ST6GAL1 (0.54) | ST6GAL1TSHRGLA | |
| Cytarabine 5'-Phosphate SCHEMBL19423351 | 0.94 | ST6GAL1 (0.47) | ST6GAL1TSHRGLAP2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL26630601 | 0.94 | ST6GAL1 (0.47) | ST6GAL1TSHRGLAP2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL15652697 | 0.93 | ST6GAL1 (0.47) | ST6GAL1TSHRGLAP2RY2 | |
| Cytarabine 5'-Phosphate SCHEMBL28842430 | 0.93 | ST6GAL1 (0.47) | ST6GAL1TSHRGLAP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113975406-A | Glycoengineered antibody drug conjugates | 建新公司 | 2022-01-28 | — | — | CN | claimed |
| US-11160874-B2 | Glycoengineered antibody drug conjugates | GENZYME CORPORATION (US) | 2021-11-02 | — | — | US | claimed |
| CN-108025083-B | Glycoengineered antibody drug conjugates | 建新公司 | 2021-09-03 | — | — | CN | claimed |
| EP-3204425-B1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORP (US) | 2020-09-16 | — | — | EP | claimed |
| US-10064952-B2 | Glycoengineered antibody drug conjugates | GENZYME CORPORATION (US) | 2018-09-04 | — | — | US | claimed |
| US-9783838-B2 | PmST3 enzyme for chemoenzymatic synthesis of alpha-2-3-sialosides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-10 | — | — | US | claimed |
| EP-3204425-A2 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | Genzyme Corporation (US) | 2017-08-16 | — | — | EP | claimed |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION | 2016-05-19 | — | — | US | claimed |
| WO-2016057769-A2 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | GENZYME CORPORATION (US) | 2016-04-14 | — | — | WO | claimed |
| CN-101778859-B | Improved process for the production of nucleotide sugars | NOVO NORDISK AS | 2014-03-26 | — | — | CN | claimed |
| CN-101778859-A | Improved process for the production of nucleotide sugars | EOSE TECHNOLOGIES INC | 2010-07-14 | — | — | CN | claimed |
| US-20080227172-A1 | SIALYLTRANSFERASE AND DNA ENCODING THE SAME | SAITO MASAKI | 2008-09-18 | — | — | US | claimed |
| EP-0886640-B1 | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES | GLYCOMIMETICS INC (US) | 2007-03-21 | — | — | EP | claimed |
| US-6949372-B2 | Engineering intracellular sialylation pathways | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-09-27 | — | — | US | claimed |
| US-20030087396-A1 | Sialyltransferase and DNA encoding the same | SEIKAGAKU CORPORATION (JP) | 2003-05-08 | — | — | US | claimed |
| US-6169077-B1 | A SIALYLATED AND FUCOSYLATED CARBOHYDRATE; USE AS ANTIADHESION THERAPEUTICS TREATING INFLAMMATIONS, THEY CAN PREVENT THE SELECTIN RECEPTORS FROM BINDING TO ACTIVATED ENDOTHELIAL CELLS ON THE SURFACE OF LEUCOCYTES | GLYCOTECH CORP. | 2001-01-02 | — | — | US | claimed |
| US-5908766-A | USING BETA GALACTOSIDE-ALPHA-2,6-SIALYLTRANSFERASE FROM PHOTOBACTERIUM TO EFFICIENTLY ADD SIALIC ACID TO 6 POSITION OF GALACTOSE RESIDUE OF GLYCOCONJUGATE, OR TO SACCHARIDE OR MONOSACCHARIDE WITH 6 POSITION HYDROXY GROUP | JAPAN TOBACCO INC. (JP) | 1999-06-01 | — | — | US | claimed |
| EP-0886640-A1 | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES | GlycoTech Corp. (US) | 1998-12-30 | — | — | EP | claimed |
| US-5827714-A | OBTAINED FROM PHOTOBACTERIUM CULTURE; TRANSFERS SIALIC ACID FROM CYTOSINE-5*-PHOSPHATE-SIALIC ACID TO THE 6-POSITION OF A GALACTOSE RESIDUE IN A SACCHARIDE OR A MONOSACCHARIDE | JAPAN TOBACCO INC. (JP) | 1998-10-27 | — | — | US | claimed |
| WO-1997028173-A1 | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES | NOVARTIS AG (CH) | 1997-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160874-B2 | Glycoengineered antibody drug conjugates | CD2BP2, B3GAT3, SIGLEC7 | ST6GAL1 29/4885NANP 284/4885TSHR 1200/4885 |
| US-20160136299-A1 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | CD2BP2, B3GAT3, SIGLEC7 | ST6GAL1 29/4885NANP 284/4885TSHR 1200/4885 |
| US-10064952-B2 | Glycoengineered antibody drug conjugates | CD2BP2, B3GAT3, SIGLEC7 | ST6GAL1 29/4885NANP 284/4885TSHR 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.